Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report

Takatori, Eriko; Shoji, Tadahiro; Miura, Yuki; Takada, Anna; Takeuchi, Satoshi; Sugiyama, Toru

doi:10.2147/ott.s54745

Cited by 7 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Tinker, et al [84] found positive results after using temsirolius for a preliminary phase II study in patients with metastatic cervical cancer. The drugs were effective when administered together with paclitaxel/carboplatin for treating stage II/IV patients with clear cell adenocarcinoma on a clinical phase II trial [85].…”

Section: The Role Of Mtor Inhibitors In Cancermentioning

confidence: 99%

mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro

Ayuk

Abrahamse

2019

Cells

View full text Add to dashboard Cite

The Mechanistic or Mammalian Target of Rapamycin (mTOR) is a major signaling pathway in eukaryotic cells belonging to the P13K-related kinase family of the serine/threonine protein kinase. It has been established that mTOR plays a central role in cellular processes and implicated in various cancers, diabetes, and in the aging process with very poor prognosis. Inhibition of the mTOR pathway in the cells may improve the therapeutic index in cancer treatment. Photodynamic therapy (PDT) has been established to selectively eradicate neoplasia at clearly delineated malignant lesions. This review highlights recent advances in understanding the role or regulation of mTOR in cancer therapy. It also discusses how mTOR currently contributes to cancer as well as future perspectives on targeting mTOR therapeutically in cancer in vitro.

show abstract

Section: The Role Of Mtor Inhibitors In Cancermentioning

confidence: 99%

mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro

Ayuk

Abrahamse

2019

Cells

View full text Add to dashboard Cite

show abstract

“… Etanercept TNF Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer [ 36 ]. Everolimus MTOR Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report [ 37 ]. Gefitinib EGFR Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells [ 38 ].…”

Section: Resultsmentioning

confidence: 99%

“…Everolimus MTOR Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report [37].…”

Section: Celecoxib Pdpk1mentioning

confidence: 99%

Integrative network analysis identifies potential targets and drugs for ovarian cancer

Zhang

2020

BMC Med Genomics

View full text Add to dashboard Cite

Background Though accounts for 2.5% of all cancers in female, the death rate of ovarian cancer is high, which is the fifth leading cause of cancer death (5% of all cancer death) in female. The 5-year survival rate of ovarian cancer is less than 50%. The oncogenic molecular signaling of ovarian cancer are complicated and remain unclear, and there is a lack of effective targeted therapies for ovarian cancer treatment. Methods In this study, we propose to investigate activated signaling pathways of individual ovarian cancer patients and sub-groups; and identify potential targets and drugs that are able to disrupt the activated signaling pathways. Specifically, we first identify the up-regulated genes of individual cancer patients using Markov chain Monte Carlo (MCMC), and then identify the potential activated transcription factors. After dividing ovarian cancer patients into several sub-groups sharing common transcription factors using K-modes method, we uncover the up-stream signaling pathways of activated transcription factors in each sub-group. Finally, we mapped all FDA approved drugs targeting on the upstream signaling. Results The 427 ovarian cancer samples were divided into 3 sub-groups (with 100, 172, 155 samples respectively) based on the activated TFs (with 14, 25, 26 activated TFs respectively). Multiple up-stream signaling pathways, e.g., MYC, WNT, PDGFRA (RTK), PI3K, AKT TP53, and MTOR, are uncovered to activate the discovered TFs. In addition, 66 FDA approved drugs were identified targeting on the uncovered core signaling pathways. Forty-four drugs had been reported in ovarian cancer related reports. The signaling diversity and heterogeneity can be potential therapeutic targets for drug combination discovery. Conclusions The proposed integrative network analysis could uncover potential core signaling pathways, targets and drugs for ovarian cancer treatment.

show abstract

“…The grade 3/4 adverse events contained hyperglycemia in 15% of patients, stomatitis syndrome 7%, pain about 5% and asthenia 5%, most of which were mild and manageable [ 25 ]. Recently, everolimus has been investigated in varieties of recurrent/metastatic tumors, including recurrent ovarian clear cell carcinoma [ 26 ], relapsed or refractory chronic lymphocytic leukemia [ 27 ] and hepatocellular carcinoma [ 28 ], and brought new hope for cancer.…”

Section: Disscussionmentioning

confidence: 99%

The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review

Zhang

Liang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Epithelioid angiosarcoma (EA) is a kind of rare malignant soft tissue sarcoma, with high recurrence/metastatic rate and poor prognosis. To date, no effective standardized treatment regimen has been available for patients with recurrence/metastatic EA. Everolimus is an oral rapamycin derivative that highly inhibits the mechanistic target of rapamycin(mTOR) signal pathway. Previous studies have suggested that everolimus is effective and safe in some soft tissue sarcoma. We reported two cases with recurrence/metastatic EA, who received everolimus after failure of surgery, radiotherapy, chemotherapy or interventional therapy. Two cases obtained clinical benefit within 1 week, and were evaluated as partial response (PR). The progression free survival (PFS) time was nearly 12.0 and 6.0 months, respectively. The overall survival (OS) time was 18.0 and 10.0 months, respectively. The main adverse event was stomatitis syndrome (grade 1-2), which was well controllable and tolerable. It indicated that everolimus may be more beneficial for recurrence/metastatic EA patients.

show abstract

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report

Cited by 7 publications

References 20 publications

mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro

mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro

Integrative network analysis identifies potential targets and drugs for ovarian cancer

The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review

Contact Info

Product

Resources

About